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Aspergillus diseases are often caused by Aspergillus fumigatus. Azoles are the mainstay
of therapy, but the management of aspergillosis is hampered by the emergence of azole
resistance. Rapid detection of azole resistance might benefit treatment outcome by early
treatment modifications. However, the yield of fungal culture in invasive aspergillosis
is low and susceptibility testing requires several days to be completed. To overcome
the low yield of fungal cultures and slow detection of resistance, it is possible to
use molecular tools directly on clinical specimens in order to rapidly detect molecular
markers of azole resistance. Molecular tools to detect resistant markers in the Cyp51A
gene can be expected to be less sensitive compared to molecular tools to detect
Aspergillus DNA as the Cyp51A gene is a single copy gene and the target for Aspergillus
DNA is often a multi-copy gene. In this mini-review, we summarize the current molecular
tools for detection of azole-resistant A. fumigatus directly in clinical material. Several
in-house PCR assays have been applied directly on clinical material. Furthermore, two
assays are commercial available; the AsperGenius and MycoGENIE. The amplification
of resistance markers was successful in 70–100% of samples that were positive for
Aspergillus DNA in BAL samples using the AsperGenius assay. Despite using several
samples per patient, amplification of resistance markers was only successful in 33–57%
of patients with Aspergillus DNA in blood. Furthermore, several sequence based
methods have been applied with the benefit of the ability to detect other Cyp51A gene
alterations.
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INTRODUCTION
Aspergillus species cause a wide spectrum of disease, including invasive aspergillosis (IA), chronic
pulmonary aspergillosis (CPA), Aspergillus bronchitis, and allergic bronchopulmonary aspergillosis
(ABPA). The most common species involved in aspergillus diseases is Aspergillus fumigatus.
If antifungal treatment is required, azoles are the first line of treatment, independently of the
manifestation of disease (Kosmidis and Denning, 2015). However, the management of aspergillosis
is hampered by the emergence of azole resistance (Verweij et al., 2016). Several case series indicate
that detection of azole resistance is associated with treatment failure (van der Linden et al., 2011;
Chong et al., 2016).
The detection of azole resistance in IA is challenging as the yield of fungal cultures is generally
low and phenotypical evaluation of azole susceptibility is therefore often impossible. Furthermore,
even if a culture is positive for A. fumigatus, susceptibility testing requires several days before results
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are available. A mature culture is recommended for MIC-testing,
which requires up to 7 days of incubation and MICs can be read
after an additional 48 h. As early treatment of patients with IA
with an appropriate drug improves outcome (Hauggaard et al.,
2002), inappropriate therapy due to azole resistance may increase
treatment failure. Nowadays it is possible to use molecular tools
directly on clinical specimens in order to rapidly detect resistance
markers. In this review, we summarize the current molecular
tools of azole resistance detection in A. fumigatus directly in
clinical material.
MOLECULAR MARKERS OF AZOLE
RESISTANCE IN A. fumigatus
The hot spot for resistance mutations in A. fumigatus is the
Cyp51A gene, a gene important for the ergosterol biosynthesis
pathway. Generally, two groups of resistance mutations can
be acknowledged; the environmental resistance mutations and
the resistance mutations due to long-term azole therapy.
TR34/L98H and TR46/Y121F/T289A are the most common
environmental resistance mutations which are now recovered
globally. Furthermore, several less prevalent environmental
resistance mutations have been reported including TR53, TR463,
and TR464 (three and four repeats of TR46, respectively)
(Zhang et al., 2017). The other group of resistance mutations
consists of point mutations in the Cyp51A gene at various
positions including G54, M220, P216, G138, and G448 with
mutations at locus G54 and M220 leading to the most common
amino acid substitutions (Meis et al., 2016; Verweij et al.,
2016).
It is estimated that 10% of azole resistance is not Cyp51A
mediated (Meis et al., 2016). Several other resistance mechanisms
have been described including increased eﬄux pump activity and
a substitution in the HapE gene (Camps et al., 2012; Fraczek
et al., 2013). Moreover, it seems likely that several other, yet
uncharacterized, mechanisms are in involved in azole resistance
in A. fumigatus.
MOLECULAR TOOLS TO DETECT
AZOLE RESISTANCE DIRECTLY IN
CLINICAL SAMPLES
Real-Time Resistance-PCR Tests
In-House Assays
The first report of the use of a qPCR for the detection of
resistance mutations on clinical samples was in 2010 in a case
of pulmonary and cerebral aspergillosis (van der Linden et al.,
2010). A pulmonary isolate was phenotypically resistant to azoles.
Brain biopsy showed septate hyphae but fungal cultures remained
negative. Sequence-based analysis of the pulmonary isolates
showed the TR34/L98H mutation and a real-time PCR was
applied on the brain tissue. For detection of the L98H mutation,
a 122-bp fragment was amplified, using a hybridization probe to
detect the L98H mutation. Furthermore, a second amplification
of a 110-bp fragment was used to detect the 34-bp insertion
(TR34) using a TaqMan probe that was designed to bind to the
last 13-bp and the first 9-bp of the 34-bp insertion. The real-
time PCR revealed the presence of a L98H mutation as well as
the 34-bp insertion (van der Linden et al., 2010). Further details
of the published papers evaluating qPCR resistance detection can
be found in Table 1.
Another in-house PCR assay was used on 29 Aspergillus DNA
positive sputum samples from patients with CPA and ABPA. In
this series a nested-PCR approach was used. The Cyp51A gene
was amplified in two fractions and a qPCR with allele-specific
molecular beacons was used to detect mutations at locus G54,
L98, G138, and M220 and to detect the 34-bp insertion. Cyp51A
was successfully amplified in all 29 Aspergillus PCR positive
samples. Four samples had a mutation at M220, 27 of 29 had
a L98H mutation of which 16 also had TR34. TR34 without
L98H was found in two patients. In two patients with a M220R
mutation, TR34 and L98H were also detected. Only four samples
were culture positive, in three the molecular results did not
correspond with the culture results (Denning et al., 2011). The
detection of either TR34 or L98H alone and a TR34/L98H with
an additional M220 mutation has not been reported in cultured
isolates, to the best of our knowledge. It seems likely that due
to fact that two genomic regions are amplificated independently
for the detection of TR34 and L98H, the amplicons were from
different strains, (e.g., a susceptible and resistant strain), resulting
in the single detection of either TR34 or L98H. The frequency of
resistance markers seems very high in this series and these results
have not yet been confirmed by other studies.
The same nested PCR-assay, with the addition of a new
molecular beacon for G448, was used to analyze 94 BAL samples.
Sixty-one of 71 (86%) samples positive for a pan-Aspergillus PCR
had a successful amplification of the Cyp51A gene. Four of the
Cyp51A negative samples were culture positive for A. flavus.
One sample contained M220V and another P216L. The authors
did not describe the use of a molecular beacon for P216L
and the mutation was thus presumably detected by subsequent
sequence analysis (Zhao et al., 2013). The high rate of TR34/L98H
mutations observed by Denning et al. (2011) was not observed in
the latter study from Denmark.
Commercial Available Assays
Results from the first commercial available resistance PCR assay,
the AsperGenius (PathoNostics, Maastricht, Netherlands) were
published in 2015. The qPCR has the ability to detect Aspergillus
DNA, and differentiates A. fumigatus and A. terreus. In addition,
four mutations (TR34 and L98H to detect TR34/L98H, Y121F,
and T289A to detect TR46/Y121F/T289A) can be detected using
melting-curve analyses. The PCR was validated on stored BAL
fluid samples from hematological and ICU patients. Of 19 BAL
fluids, 16 were positive for Aspergillus DNA, whereas 14 of
16 were positive for A. fumigatus. All 14 samples were also
positive for resistance targets and mutation analyses revealed
12 samples with WT Cyp51A DNA, one TR34/L98H and one
TR46/Y121F/T289A (Chong et al., 2015).
The assay was validated prospectively in a multicenter study
in 201 patients with hematological disease suspected for IA.
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The Aspergillus PCR was positive in 97 samples (74 samples
with either galactomannan (GM)-index >1 or with a positive
culture) and the resistance PCR was successful in 68 of 97 (70%)
samples. In 7 samples TR34/L98H was detected, in one sample
TR46/Y121F/T289A, while a combination of TR34/L98H and
WT A. fumigatus was observed in three samples. Importantly,
this study showed that the detection of resistance markers was
associated with azole treatment failure; even in culture-negative
cases (Chong et al., 2016).
Another study used the assay on 45 GM-positive BAL samples
and 55 GM-negative BAL samples. Twenty-seven of 100 patients
were positive for Aspergillus DNA and 20 for A. fumigatus DNA.
The amplification of resistance markers appeared to be successful
in all A. fumigatus positive samples and evidence for azole
resistance was found in three (Montesinos et al., 2017).
Other studies have evaluated the AsperGenius assay directly
on blood samples, for early detection of Aspergillus disease in
patients at risk for IA (White et al., 2015a). The assay was
evaluated on serum samples from 14 patients with proven or
probable IA (total 54 extracts). A. fumigatus DNA was detected
in 25 of 54 samples. The amount of DNA in the serum, however,
was low and only 12 samples of 7 cases had sufficient DNA-
levels for the resistance PCR to be performed reflecting the lower
sensitivity of the resistance PCR compared to the Aspergillus
DNA assay. Samples from four patients (57%) had 3–4 loci
(TR34, L98H, T289A, or Y121F) amplified and 50% of all patients
had at least one loci amplified. Mutation analyses showed no
mutations in these patients. Thus despite using multiple samples
per patient; genotyping both TR34/L98H and TR46/Y121F/T289A
was possible in only four of 14 patients with proven/possible IA.
For successful amplification of resistance markers, a Ct value of
<33 was needed in the A. fumigatus assay (White et al., 2015b).
As the performance of Aspergillus-PCR was shown to be
superior on plasma compared to serum, it was hypothesized
that plasma was also superior for the detection of resistance
markers (White et al., 2015a). Eighty-six plasma samples from 10
patients with proven/probable IA and two patients with possible
IA were tested. Eleven samples from six patients were positive for
A. fumigatus. Amplification of resistance markers was successful
in only two of six (33%) patients. Thus, using a mean of seven
samples per patient, the resistance markers were successfully
amplified in only two of 12 (17%) patients with IA. However,
as the A. fumigatus PCR was only positive in six of 12 patients
and all culture results were negative, it is not known whether
the IA was due to A. fumigatus in the other patients (White
et al., 2017). As the target for azole resistance detection is a
single copy gene, the sensitivity can be expected to be lower
than the Aspergillus DNA assay for which a multi-copy gene
is targeted. The results of PCR used on blood samples clearly
reflects this lower sensitivity and due to the low amount of
DNA in blood samples, clinical utility in routine diagnostics is
questionable.
An interesting advantage of the AsperGenius PCR is the
simultaneous detection of both WT and mutant Cyp51A DNA.
As the detection of resistance markers is based on melting curve
analysis, mixed infections with both WT as well as DNA from
resistant strains will result in two peaks in the assay. This was
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shown in three cases were evidence for both WT and L98H was
found (Schauwvlieghe et al., 2017).
A report of a second commercial available assay, the
MycoGENIE (Ademtech, Pessac, France), was published in 2017.
The MycoGENIE is a multiplex assay detecting A. fumigatus
DNA, the L98H mutation and TR34. The PCR was tested
on a total of 55 serum samples from 16 patients and 88
respiratory samples from 62 patients. Fifty-Five respiratory and
16 serum samples were positive for A. fumigatus (Dannaoui
et al., 2017). The same MycoGENIE was then used on stored
clinical samples from 137 patients with fungal rhinosinusitis with
a positive microscopy for fungal hyphae. The PCR was positive
for A. fumigatus in 116 of 147 samples (78.9%), whereas 47 of 48
A. fumigatus culture positive samples were positive in the assay
(Morio et al., 2018). In both studies no samples were positive for
either TR34 or L98H.
An important limitation of the MycoGENIE is the absence
of WT probes for the resistance marker. As a consequence,
non-positivity in the resistance markers might be caused a
WT genotype but might also be due to a missed mutation due
to limited sensitivity compared to the probe for detection
of A. fumigatus DNA. Furthermore, the less prevalent
environmental TR46/Y121F/T289A mutation is not detected by
the MycoGENIE.
Sequence Based Assays
In addition to direct qPCR assays, several other methods
have been applied directly to clinical specimen (Table 2).
Amplification with subsequent pyrosequencing was applied
directly on blood samples to detect G54 mutations in the Cyp51A
gene. A. fumigatus DNA was detected in two of 56 whole-blood
samples targeting a 269-p Cyp51A gene region and Cyp51A
sequence of locus G54 was determined. The study showed the
utility of amplification and subsequent sequencing of clinical
material for detection of Cyp51A-mutations (Trama et al., 2005).
Most other loci were not covered by the targeted region but this
can be overcome by sequencing of additional Cyp51A regions
involved in azole resistance.
Other authors generated additional primers for the specific
amplification and subsequent sequencing of the A. fumigatus
Cyp51A-gene. Three different primer sets were used for the
amplification of the Cyp51A promoter region, L98 and M220
regions. Eight stored clinical samples were tested and TR34/L98H
was successfully detected in a brain abscess. Interestingly, in
one BAL fluid, L98H was found without the TR34 (Spiess et al.,
2012). Using the same method with the addition of another
target region for the detection of TR46, stored clinical samples of
155 immunocompromised patients previously tested positive for
Aspergillus DNA were evaluated. In 75 of 181 (41%) investigated
samples, the assay was positive for at least one region. The L98H
region alone was successfully amplified and sequenced in 26
(14%), the regions for L98H and TR34 in 17 (9%); both revealed
no mutations. In 22 of 181 (12%) samples the L98H, TR34 as well
as the M220 PCR targets were successfully amplificated, showing
two samples with both the TR34 and L98H mutations. One
sample had L98H but not TR34 (Spiess et al., 2014). Higher rate
of successful amplification was achieved by a nested approach. TA
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The sequence method described by Denning et al. (2011) was
used but without the molecular beacons. The Cyp51A was
successfully amplified in 38 of 44 (86%) pan-Aspergillus PCR
positive samples. Using this technique, the authors found a
sputum sample harboring TR34/L98H, which was confirmed by
culture (Zhao et al., 2016).
CONCLUSION AND PERSPECTIVES
The application of molecular tools has been shown to
increase the sensitivity of detection of azole resistance in
A. fumigatus compared to culture. Furthermore, the detection
of resistance markers in BAL samples using the AsperGenius
was associated with increased probability of azole treatment
failure. The commercial available assays target TR34/L98H and
TR46/Y121F/T289A mutations and are able to detect most of
azole-resistant A. fumigatus in patients with acute IA. However,
the clinical utility depends on regional resistance epidemiology.
In patients with prolonged azole therapy, a greater diversity
of resistance mutations should be taken into consideration.
Detection of resistance markers in blood samples remains
problematic; nonetheless if very low Ct value in the Aspergillus
PCR is observed, resistance markers might be successfully
detected.
Direct amplification and subsequent sequencing of
the Cyp51A-gene showed the potential to cover most
Cyp51A-mediated resistance mutations. However, compared
to real-time assays, sequencing is relatively time-consuming,
expensive and laborious, and might lack sensitivity due to
low amounts of DNA in most clinical samples. Furthermore,
compared to the commercial qPCR assay for detection of azole
resistance, clinical validation studies are currently lacking.
New molecular assays should aim to increase sensitivity
and extend the coverage of resistance markers to include both
environmental as other azole resistance mutations. Sequencers
have become portable, inexpensive and can be used in real time.
When the capacity of whole genome sequencing increases in
the near future, it seems likely that whole genome sequencing
can be applied directly on clinical specimens to detect not
only the pathogen, but also a wide range of resistance
mechanisms.
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